{"entity":{"id":"rgt-61159","kind":"drug","name":"RGT-61159","aka":[],"tldr":"RGT-61159 is an experimental small molecule from Rgenta Therapeutics, in phase 1 trials for relapsed or refractory adenoid cystic carcinoma and colorectal cancer.","summary":"RGT-61159 is a small molecule (oral RNA splicing modulator) from Rgenta Therapeutics. An oral small molecule designed to change the splicing of the MYB transcription factor's RNA, which stops production of the cancer-driving MYB protein. Its furthest stage is phase 1, for relapsed or refractory adenoid cystic carcinoma and colorectal cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1a/b NCT06462183 (alone and with lenvatinib) active, not recruiting. Company news page lists a release of 22 October 2026 announcing a successful end-of-phase 2 meeting with the FDA and alignment on a phase 3 design in adenoid cystic carcinoma. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Rgenta Therapeutics: prnewswire.com","url":"https://www.prnewswire.com/news-releases/rgenta-therapeutics-announces-first-patients-dosed-in-phase-1ab-clinical-trial-of-rgt-61159-an-oral-small-molecule-targeting-myb-in-adenoid-cystic-carcinoma-acc-and-colorectal-cancer-crc-302269345.html"},{"label":"Rgenta Therapeutics: rgentatx.com","url":"https://www.rgentatx.com/news"},{"label":"Rgenta Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT06462183"},{"label":"ClinicalTrials.gov: trials of RGT-61159","url":"https://clinicaltrials.gov/search?intr=RGT-61159"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["adenoid-cystic-carcinoma","colorectal"],"sections":[],"technologies":[],"targets":["myb"],"drugs":[],"companies":["rgenta-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06462183"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"RGT-61159","modality":"Small molecule (oral RNA splicing modulator)","mechanism":"An oral small molecule designed to change the splicing of the MYB transcription factor's RNA, which stops production of the cancer-driving MYB protein.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/rgt-61159/","neighbours":{"cancer":[{"id":"adenoid-cystic-carcinoma","kind":"cancer","name":"Adenoid cystic carcinoma","route":"/cancers/adenoid-cystic-carcinoma/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"target":[{"id":"myb","kind":"target","name":"MYB","route":"/targets/myb/"}],"company":[{"id":"rgenta-therapeutics","kind":"company","name":"Rgenta Therapeutics","route":"/companies/rgenta-therapeutics/"}],"trial":[{"id":"nct06462183","kind":"trial","name":"Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)","route":"/trials/nct06462183/"}]}}